000026826 000__ 02743cam\a2200601\i\4500
000026826 001__ 26826
000026826 003__ SzGeWIPO
000026826 005__ 20230704115258.0
000026826 008__ 111024s2012\\\\gw\\\\\\rbj\\\000\0\eng\d
000026826 020__ $$a9783642248450
000026826 020__ $$a9783642248467$$qelectronic book
000026826 035__ $$a(wipo)0
000026826 035__ $$a(OCoLC)780264660
000026826 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000026826 041__ $$aeng
000026826 050_4 $$aK1519.B54$$bH828 2012
000026826 08204 $$a340$$220
000026826 08204 $$a660.60272$$223
000026826 084__ $$aG 25 HUB.B
000026826 090__ $$c29226$$d29215
000026826 1001_ $$aHübel, Andreas,$$d1964-$$eauthor.
000026826 24510 $$aBiopatent law :$$bpatent strategies and patent management /$$cAndreas Hübel, Thilo Schmelcher, Ulrich Storz.
000026826 264_1 $$aHeidelberg :$$bSpringer,$$cc2012.
000026826 300__ $$axii, 44 pages ;$$c23 cm.
000026826 336__ $$atext$$btxt$$2rdacontent
000026826 337__ $$aunmediated$$bn$$2rdamedia
000026826 338__ $$avolume$$bnc$$2rdacarrier
000026826 4901_ $$aSpringerBriefs in biotech patents,$$x2192-9904
000026826 500__ $$aGeneral issues of biotech patents. Active and passive patent strategies. Patent lifecycle management, supplementary protection certificates and data exclusivity in biopharmaceutics.
000026826 5050_ $$aGeneral issues of biotech patents; Active and passive patent strategies; Patent lifecycle management, supplementary protection certificates and data exclusivity in biopharmaceutics.
000026826 520__ $$aPatents protecting biotechnological invention become ever more important. Because biotechnology has many differences with respect to other technologies, lessons learned in other fields of technology cannot simply be transferred to adopt a suitable strategy for dealing with biotechnology inventions. In this volume, general aspects of biopatent law will be discussed. This involves questions of patentability, including ethical issues and issues of technicality, as well as questions of patent exhaustion in cases were reproducible subject matter, like cells or seeds, is protected. Moreover, active and passive patent strategies are addressed. Further, insight will be given into patent lifetime management and additional protective measures, like supplementary protection certificates and data exclusivity. Here, strategies are discussed how market exclusivity can be extended as long as possible, which is particularly important for biopharmaceutical drugs, which create high R & D costs.
000026826 650_0 $$aLife sciences.
000026826 650_0 $$aBiotechnology.
000026826 650_0 $$aMicrobiology.
000026826 650_0 $$aBiochemistry.
000026826 650_0 $$aCytology.
000026826 650_0 $$aCommercial law.
000026826 650_0 $$aBiotechnology$$vPatents.
000026826 650_0 $$aPharmaceutical technology.
000026826 650_0 $$aPatents.
000026826 650_4 $$aPatents
000026826 650_4 $$aLitigation
000026826 650_6 $$aBiotechnologie$$xBrevets d'invention.
000026826 655_7 $$aPatents.$$2lcgft
000026826 7001_ $$aSchmelcher, Thilo.
000026826 7001_ $$aStorz, Ulrich,$$d1969-
000026826 7001_ $$aHübel, Andreas,$$d1964-
000026826 830_0 $$aSpringerBriefs in biotech patents,.
000026826 942__ $$cMON$$jG 25 HUB.B
000026826 952__ $$w2012-09-25$$p2012-0229$$r42.00$$u41304$$bMAIN$$10$$kG 25 HUB.B$$v2012-09-25$$zTagged$$71
000026826 980__ $$aBIB
000026826 999__ $$c29226$$d29226